Dr. Amer Zeidan from Yale School of Medicine explains the uses, benefits, and risks of the newly approved treatment, Inqovi.

Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.

Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator. Dr. Steensma is an associate professor at Harvard Medical School and faculty member in the leukemia program at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts and the Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute

Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPNs overlap. He includes how molecular testing is used in determining treatment options. He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.

During COVID-19, the PAN Foundation is giving grants to certain AML and CML patients. Listen to this broadcast to learn the details.

Discussion of the recent approval of Luspatercept with Doctor Amit Verma, Director of the Division of Hematologic Malignancies and a Professor of Oncology at the Albert Einstein College of Medicine in New York City. #MDS #treatingMDS

Dr. Gustavo Rivero describes strategies for management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.

Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.

Julie Lowe, AAMDSIF Director for Strategic Initiatives, anticipates your questions about getting involved with the Aplastic Anemia and MDS International Foundation in this recent interview.

Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.